X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 91 filers reported holding X4 PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.69 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $677,318 | +123.0% | 349,133 | 0.0% | 0.11% | +56.5% |
| Q1 2023 | $303,745 | -12.4% | 349,133 | 0.0% | 0.07% | -17.9% |
| Q4 2022 | $346,689 | -64.4% | 349,133 | -38.6% | 0.08% | -56.7% |
| Q3 2022 | $973,000 | -40.0% | 568,612 | -66.1% | 0.19% | -34.5% |
| Q2 2022 | $1,621,000 | -32.5% | 1,679,748 | +22.4% | 0.30% | -6.3% |
| Q1 2022 | $2,402,000 | -53.7% | 1,372,022 | -39.4% | 0.32% | -59.1% |
| Q4 2021 | $5,186,000 | -61.4% | 2,264,491 | -10.8% | 0.77% | -18.3% |
| Q3 2021 | $13,437,000 | -24.0% | 2,539,917 | -6.6% | 0.95% | -33.8% |
| Q2 2021 | $17,676,000 | -21.5% | 2,719,290 | +4.0% | 1.43% | +88.5% |
| Q1 2021 | $22,515,000 | +323.7% | 2,614,988 | +216.4% | 0.76% | +223.9% |
| Q4 2020 | $5,314,000 | +8.3% | 826,424 | +14.0% | 0.23% | -34.1% |
| Q3 2020 | $4,907,000 | +10340.4% | 724,680 | +14393.6% | 0.36% | +8775.0% |
| Q2 2020 | $47,000 | -56.1% | 5,000 | -50.0% | 0.00% | -76.5% |
| Q4 2019 | $107,000 | – | 10,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 311,492 | $2,109,000 | 3.48% |
| SV Health Investors, LLC | 311,490 | $2,109,000 | 1.07% |
| Bain Capital Life Sciences Investors, LLC | 1,648,485 | $11,160,000 | 1.04% |
| New Leaf Venture Partners, L.L.C. | 335,000 | $2,268,000 | 0.91% |
| Ikarian Capital, LLC | 724,680 | $4,907,000 | 0.36% |
| BVF INC/IL | 792,892 | $5,368,000 | 0.29% |
| Opaleye Management Inc. | 75,000 | $508,000 | 0.10% |
| Orbimed Advisors | 1,086,493 | $7,356,000 | 0.09% |
| RA Capital Management | 559,494 | $3,788,000 | 0.07% |
| Bleichroeder LP | 35,730 | $242,000 | 0.04% |